Abonnement à la biblothèque: Guest
Critical Reviews™ in Therapeutic Drug Carrier Systems

Publication de 6  numéros par an

ISSN Imprimer: 0743-4863

ISSN En ligne: 2162-660X

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) IF: 2.7 To calculate the five year Impact Factor, citations are counted in 2017 to the previous five years and divided by the source items published in the previous five years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) 5-Year IF: 3.6 The Immediacy Index is the average number of times an article is cited in the year it is published. The journal Immediacy Index indicates how quickly articles in a journal are cited. Immediacy Index: 0.8 The Eigenfactor score, developed by Jevin West and Carl Bergstrom at the University of Washington, is a rating of the total importance of a scientific journal. Journals are rated according to the number of incoming citations, with citations from highly ranked journals weighted to make a larger contribution to the eigenfactor than those from poorly ranked journals. Eigenfactor: 0.00023 The Journal Citation Indicator (JCI) is a single measurement of the field-normalized citation impact of journals in the Web of Science Core Collection across disciplines. The key words here are that the metric is normalized and cross-disciplinary. JCI: 0.39 SJR: 0.42 SNIP: 0.89 CiteScore™:: 5.5 H-Index: 79

Indexed in

The Use and Development of Retroviral Vectors to Deliver Cytokine Genes for Cancer Therapy

Volume 17, Numéro 1, 2000, 60 pages
DOI: 10.1615/CritRevTherDrugCarrierSyst.v17.i1.10
Get accessGet access

RÉSUMÉ

In this review, we describe technical advancements of retroviral vectors to address issues of safety, liter, and clinical scale manufacturing to produce high-quality retroviral vector preparations that have made direct intratumoral administration of cytokine encoding recombinant vectors a feasible cancer therapy in the clinic. We also review possible further advances in retroviral vector design, which may prove important in expanding these clinical applications.

CITÉ PAR
  1. Wu Dai-Tze, Roth Monica J., MLV based viral-like-particles for delivery of toxic proteins and nuclear transcription factors, Biomaterials, 35, 29, 2014. Crossref

  2. Page David T, Cudmore Sally, Innovations in oral gene delivery: challenges and potentials, Drug Discovery Today, 6, 2, 2001. Crossref

  3. Mohan Rajiv R., Sharma Ajay, Netto Marcelo V., Sinha Sunilima, Wilson Steven E., Gene therapy in the cornea, Progress in Retinal and Eye Research, 24, 5, 2005. Crossref

  4. Smith Kevin R, Gene therapy: theoretical and bioethical concepts, Archives of Medical Research, 34, 4, 2003. Crossref

  5. Lundqvist Andreas, Noffz Gabriele, Pavlenko Maxim, Sæbøe-Larssen Stein, Fong Timothy, Maitland Norman, Pisa Pavel, Nonviral and Viral Gene Transfer Into Different Subsets of Human Dendritic Cells Yield Comparable Efficiency of Transfection, Journal of Immunotherapy, 25, 6, 2002. Crossref

  6. Zöller Margot, Immunotherapy of Cancer by Active Vaccination: Does Allogeneic Bone Marrow Transplantation after Non-Myeloablative Conditioning Provide a New Option?, Technology in Cancer Research & Treatment, 2, 3, 2003. Crossref

Portail numérique Bibliothèque numérique eBooks Revues Références et comptes rendus Collections Prix et politiques d'abonnement Begell House Contactez-nous Language English 中文 Русский Português German French Spain